MedTrace Logo

ABI-008 Trial in Patients With Metastatic Breast Cancer

NCT00531271 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2019-11-14

No results posted yet for this study

Summary

To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-008 giver every 3 weeks; to characterize the toxicities of ABI-008; and to determine the pharmacokinetic parameters for ABI-008 when given on an every-3-week schedule to patients with metastatic breast cancer.

Conditions

Interventions

DRUG

ABI-008 (nab-docetaxel)

ABI-008; 60-200 mg/m²; Intravenous infusion every 3 weeks.

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Nuhad Ibrahim, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-01
Primary Completion
2008-12-01
Completion
2008-12-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00531271 on ClinicalTrials.gov